INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 4

Sheet

	Complete if Known
Application Number	10/787,018
Filing Date	02-24-2004
First Named Inventor	Gosling, Jennifa
Art Unit	Not Yet known—1646
Examiner Name	NOLYELKNOWN-MICHAEL PALL
Attorney Docket Number	019934-000723US

		U.S. PA	TENT DOCUME	NTS+		
	_	Document Number			•	
Examiner traitials*	Cite No.1	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
MOP	A1	US-5,932,445	8-03-1999	Lal et al.		
X	A2	US-6,110,695	8-29-2000	Gunn et al.		
	A3	US-2001/0016336 A1	8-23-2001	Ellis		
	A4	U.S. Patent Application No. 09/686,020		Gosling et al.		
	A5	U.S. Patent Application No. 09/721,341		Gosling et al.		
-₩	A6	U.S. Patent Application No. 09/686,019		Gosling et al.		
MDP	A7	U.S. Patent Application No. 09/721,495		Gosling et al.		

			FC	REIGN	PATENT DO	CUMENTS		
Examiner Cite No.1	Cite	Foreig	n Patent Document				Pages, Columns, Lines, Where Relevant	
	Country Code ³		d Code ^b (if known)	Date MM-DD-	te MM-DD- Name of Patentee or Applicant of		ן די	
MOP	B1	EP	0 899 332	A2	03-03-1999	Smith Kline Beecham		回
∧	B2	PCT	WO 99/24463	A2	05-20-1999	Incyte Pharmaceuticals, Inc.		
	B3	PCT	WO 99/33876	A1	07-08-1999	Asahi Kasei Kogyo Kabushiki		
	B4	PCT	WO 99/52945	A2	10-21-1999	Millenium Pharmaceuticals, Inc.		
4	B5	PCT	WO 00/26369	A1	05-11-2000	Chiron Corporation		
MOP	B6	PCT	WO 00/64941	A2	11-02-2000	Curagen Corporation		

Examiner Signature	MICHAEL	Pau	Date Considered	9-21005

Substitute	Substitute for form 1449B/PTO				Complete if Known
				Application Number	10/787,018
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	02-24-2004	
STAT			First Named Inventor	Gosling, Jennifa	
				Art Unit	Not yet known 1646
((use as many sheets as necessary)		Examiner Name	Not yet known:	
Sheet	Sheet 2 of 4		Attorney Docket Number	019934-000723US	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
MOP	C1	DATABASE EMBL Accession No. Q9NPB9; 1 October 2000	
1	C2	DATABASE EMBL Accession No. Y30125; 14 October 1999	
	СЗ	GenBank Accession Number AA215577; August 13, 1997	
	C4	GenBank Accession Number AF233281; May 22, 2000	
	C5	GenBank Accession Number Al131555; October 26, 1998	
	C6	GenBank Accession Number Al769466; June 28, 1999	
	C7	GenBank Accession Number AR003970; December 10, 1998	
	С8	GenBank Accession Number AW190975; November 22, 1999	
	C9	GenBank Accession Number E12852; June 24, 1998	
	C10	GenBank Accession Number H67224; October 27, 1995	
1/4	C11	BAGGIOLINI, M. "Chemokines in pathology and medicine." Journal Internal Medicine, 2001, pp. 91-104, Vol. 250.	
	C12	BORK, PEER, et al; Go hunting in sequence databases but watch out for the traps; <i>Trends in Genetics</i> ; October 1996; pp. 425-427; Vol. 12, No. 10	
	C13	BORK, PEER; Powers and Pitfalls in Sequence Analysis: The 70% Hurdle; Genome Research; 2000; pp. 398-400; Vol. 10	
	C14	BRENNER, Steven E.; Errors in genome annotation; <i>Trends in Genetics</i> ; April 1999; pp. 132-133; Vol. 15, No. 4	
\downarrow	C15	DAIRAGHI, DANIEL J.;, et al. Chemokine Receptor CCR3 Function Is Highly Dependent on Local pH and Ionic Strength; The Journal of Biological Chemistry; November 7, 1997; pp. 28206-28209; Volume 272, No. 45	
MOP	C16	DAIRAGHI, DANIEL J. et al.; HHV8-encoded vMIP-I Selectively Engages Chemokine Receptor CCR8; The Journal of Biological Chemistry; July 30, 1999; pp. 21569-21574; Volume 274, No. 31	

Examiner	1. 01		Date	
Signature	MICHAEL	PAL	Considered	9-21-05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional), Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO Complete if Known Application Number 10/787,018 INFORMATION DISCLOSURE 02-24-2004 Filing Date STATEMENT BY APPLICANT First Named Inventor Gosling, Jennifa Art Unit Not yet known 1646 (use as many sheets as necessary) Not yet known Examiner Name 019934-000723US Sheet Attomey Docket Number

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
MOP	C17	DOERKS, TOBIAS, et al.; Protein annotation: detective work for function prediction; <i>Trends in Genetics</i> ; June 1998; pp. 248-250; Vol. 14, No. 6	
1	C18	GOSLING, JENNIFA, et al; Cutting Edge: Identification of a Novel Chemokine Receptor That Binds Dendritic Cell-and T Cell-Active Chemokines Including ELC, SLC, and TECK; The Journal of Immunology; 2000; pp. 2851-2856	
	C19	KHOJA, HAMIDUDDIN, et al.; Cloning of CCRL1, an orphan seven transmembrane receptor related to chemokine receptors, expressed abundantly in the heart; Gene; 2000; pp. 229-238; Volume 246	
	C20	HULME, E.C., editor; Receptor-Ligand Interactions A Practical Approach; 1992; Preface, Table of Contents, Chapters 6,7, 8 and 9; pp. viii-xv and 213-263; IRL Press at Oxford University Press Inc., New York, New York	
	C21	MATSUOKA, ICHIRO et al.; Identification of Novel Members of G-Protein Coupled Receptor Superfamily Expressed in Bovine Taste Tissue; Biochemical and Biophysical Research Communications; July 15, 1993; pp. 504-511; volume 194, No. 1	
F	C22	MURPHY, P. "International Union of Pharmacology. XXX. Update on Chemokine Receptor Nomenclature" Pharmacological Reviews, 2002, pp. 227-229, Vol. 54, USA.	
	C23	NGO, J. THOMAS, et al; Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox; <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , K. Merz, Jr. and S. LeGrand, Editors; 1994; pp. 491-495; Birkhauser, Boston	
	C24	O'DOWD, BRIAN F., et al.; A novel gene codes for a putative G protein-coupled receptor with an abundant expression in brain; FEBS Letters 1996; pp 325-329	
	C25	SCHWEICKART, VICKI L. et al.; CCR11 Is a Functional Receptor for the Monocyte Chemoattractant Protein Family of Chemokines; The Journal of Biological Chemistry; March 31, 2000; pp. 9550-9556; volume 275, No. 13.	
-	C26	SISSORS, DANIEL L., et al.; A Homogeneous Receptor Binding Assay for HTS on FlashPlate® Plus; NEN® Life Science Products, Inc.; 1999; pp. 1-7	
	C27	SKOLNICK, JEFFREY, et al; From gene to protein structure and function: novel applications of computational approaches in the genomic era; <i>Trends in Biotech</i> ; 2000; pp. 34-39; Vol. 18, No. 1	
V	C28	SMITH, TEMPLE F., et al; The challenges of genome sequence annotation or "The devil is in the details"; Nature Biotechnology; November 1997; pp. 1222-1223; Vol. 15	
Mof	C29	TOWNSON, JANE R., et al.; Characterization of mouse CCX-CKR, a receptor for the lymphocyte-attracting chemokines TECK/mCCL25, SLC/mCCL21 and MIP-3ß/mCCL19: comparison to human CCX-CKR; Eur. J. Immunot, 2002; pp. 1230-1241; Volume 32	

Examiner Signature	MICHAEL P	'AK	Date Considered	9-21-05
Signature	MUCHEL	HL	Considered	1-4.0

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO Complete if Known Application Number 10/787,018 INFORMATION DISCLOSURE 02-24-2004 Filing Date STATEMENT BY APPLICANT First Named Inventor Gosling, Jennifa Art Unit Not yet known 1646 (use as many sheets as necessary) Examiner Name Not yet known 019934-000723US Attorney Docket Number Sheet

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
MOP	C30	Wells, James A.; Additivity of Mutational Effects in Proteins; <i>Biochemistry</i> ; September 18, 1990; pp. 8509-8517; Vol. Vol. 29, No. 37	

Examiner Signature MICHAEL PAK Considered 9-21-65

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.